<--- Back to Details
First PageDocument Content
Tumor markers / Carcinogenesis / BRCA1 / Breast cancer / BRCA2 / Michael Wigler / Cancer / Ovarian cancer / Evelyn Lauder / Medicine / Oncology / Tumor suppressor genes
Date: 2015-04-09 14:57:54
Tumor markers
Carcinogenesis
BRCA1
Breast cancer
BRCA2
Michael Wigler
Cancer
Ovarian cancer
Evelyn Lauder
Medicine
Oncology
Tumor suppressor genes

I bodywise much as $14 million among approximately 70 researchers. "Some of the most recent research is the most exciting," says Lauder,

Add to Reading List

Source URL: amyblumenfeld.com

Download Document from Source Website

File Size: 1,66 MB

Share Document on Facebook

Similar Documents

Journal of Machine Learning ResearchSubmitted 8/15; Revised 3/16; PublishedStructure-Leveraged Methods in Breast Cancer Risk Prediction

Journal of Machine Learning ResearchSubmitted 8/15; Revised 3/16; PublishedStructure-Leveraged Methods in Breast Cancer Risk Prediction

DocID: 1vq0d - View Document

Multicausality: Confounding - Assignment solutions 1. a. Reserpine is a risk factor. Overall, the incidence of breast cancer isper 100,000 women-years in reserpine users and 6.14 per 100,000 women-years in nonuser

Multicausality: Confounding - Assignment solutions 1. a. Reserpine is a risk factor. Overall, the incidence of breast cancer isper 100,000 women-years in reserpine users and 6.14 per 100,000 women-years in nonuser

DocID: 1vpNA - View Document

Frequently Asked Questions: Trainees seeking a PhD education in Cancer Biology or a related area with a focus on Breast Cancer Health Disparities. 1. What is the Komen Graduate Training in Disparities Research Grant (GT

DocID: 1voV1 - View Document

_____________________________________________________________  What to Do When Someone You Know Has Been Diagnosed with Breast Cancer [Last revised Mar 2014]

_____________________________________________________________ What to Do When Someone You Know Has Been Diagnosed with Breast Cancer [Last revised Mar 2014]

DocID: 1vlqg - View Document

Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1–mediated metabolism to the product 4′ hydroxy tangeretin

Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1–mediated metabolism to the product 4′ hydroxy tangeretin

DocID: 1vl9e - View Document